02.06 / Life Sciences Capital
The capital thatfunds scientific innovation.
Provides non-dilutive capital to biopharmaceutical and medical technology companies, universities and royalty holders through royalty monetizations, synthetic royalties and structured credit. An investor and financier, not a drug developer. A platform in formation.
UpManagement Crucible
Company
06
UpManagement Crucible
Offices
3
Dallas · Washington, D.C. · Houston
Status
F
Platform in formation
Parent
1
UpManagement, sole member
01 / The problem
Whatis broken.
Life sciences innovation is capital intensive and slow to pay back, and the instruments available to innovators are poorly matched to their assets. Equity is dilutive when valuations are volatile, conventional lenders struggle to underwrite patents and approvals, and universities hold long-dated royalty streams they cannot easily value or sell. The largest royalty investors focus on large transactions, leaving the middle market underserved.
02 / What Crucible does
Ourapproach.
Three instruments
Royalty monetization, synthetic royalties and revenue interest financings, and structured credit.
Integrated diligence
Science, clinical data, FDA and CMS regulation, patents and exclusivity, commercial and pricing dynamics, in-house.
Structural protection
Risk-adjusted valuation with explicit downside cases: caps, step-ups, puts, covenants and milestone-contingent funding.
Regional origination
Dedicated academic tech-transfer and royalty-holder coverage from our offices.
03 / Offerings
What wedeliver.
Business model
Returns come from contractual royalty receipts, revenue interest payments and interest and fees on structured credit, driven by the net sales of approved products rather than by corporate profitability. Investment adviser registration and other approvals: not yet in place.
UpManagement Crucible
Royalty monetization for universities, research institutes, inventors and licensors
Synthetic royalties on future net sales of a specified product
Revenue interest financings with caps and step-downs
Structured credit secured by IP and commercial assets
Medtech and diagnostics financing
Academic royalty solutions that respect Bayh-Dole and institutional mission
04 / Who we serve
Built forthree kinds of customer.
01
Biopharma and medtech companies
Commercial-stage or near-commercial companies seeking non-dilutive capital.
02
Universities and research institutes
Holders of royalty streams on licensed inventions.
03
Inventors and royalty holders
Individuals and licensors with long-dated, concentrated royalty interests.
05 / Why now
The moment forCrucible.
Equity for life sciences companies is expensive and volatile, raising demand for non-dilutive alternatives
The largest royalty investors are moving upmarket, leaving the middle market less crowded
Universities and inventors want liquidity without giving up their mission
06 / At a glance
Cruciblein brief.
Legal entity
UpManagement Crucible LLC
Parent
UpManagement (sole member).
Sector
Life Sciences Capital
Offices
Dallas · Washington, D.C. · Houston
Leadership
Led by its President, who reports to the UpManagement Chief Operating Officer.
Status
Platform in formation. Regulatory approvals and clearances are not yet in place.
Endorsed form
Crucible, an UpManagement company
Inquiries
crucible@theupmgmt.com · 945-419-8600
07 / Insights
Notes fromCrucible.
Three pieces on life sciences capital, published by UpManagement.
All insights
